Harrow, Inc. (NASDAQ:HROW – Get Free Report) was the target of a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 4,980,000 shares, a decline of 9.5% from the April 30th total of 5,500,000 shares. Based on an average daily volume of 510,400 shares, the […]
Chardan Capital assumed coverage on shares of iBio (NYSE:IBIO – Free Report) in a report released on Tuesday, MarketBeat.com reports. The brokerage issued a buy rating and a $5.00 price target on the stock. Separately, StockNews.com started coverage on iBio in a research note on Saturday, April 20th. They issued a sell rating for the […]
Shares of Harrow, Inc. (NASDAQ:HROW – Get Free Report) traded down 5.8% on Wednesday . The company traded as low as $17.45 and last traded at $17.49. 215,167 shares changed hands during mid-day trading, a decline of 54% from the average session volume of 464,695 shares. The stock had previously closed at $18.56. Analyst Upgrades […]
Protara Therapeutics, Inc. (NASDAQ:TARA – Get Free Report) major shareholder Opaleye Management Inc. sold 33,000 shares of the stock in a transaction dated Tuesday, May 21st. The shares were sold at an average price of $3.06, for a total transaction of $100,980.00. Following the sale, the insider now directly owns 124,250 shares of the company’s […]
Harrow, Inc. (NASDAQ:HROW – Free Report) – B. Riley dropped their Q2 2024 earnings per share (EPS) estimates for Harrow in a research report issued to clients and investors on Tuesday, May 14th. B. Riley analyst M. Mamtani now expects that the company will earn ($0.25) per share for the quarter, down from their previous […]